Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Blood samples | Other | Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen. | ||
| Samples from tumor draining vessels | Other | In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival (OS) in heterogeneous cancer population | overall survival (OS) in heterogeneous cancer population | Screening (Visit 1) until the date of death (assessed up to 240 months) |
| Change in total number of isolated CTCs | Change in total number of isolated CTCs | Through study completion, an average of 20 years |
| Measure | Description | Time Frame |
|---|---|---|
| Progression free survival (PFS) | progression free survival (PFS) in the different cancer cohorts with different treatment regimes | Through study completion, an average of 20 years |
| Measure | Description | Time Frame |
|---|---|---|
| Change in circulating tumor DNA (ctDNA) from blood samples | Change in circulating tumor DNA (ctDNA) from blood samples | Through study completion, an average of 20 years |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
adult patients (> 18 years) with a cancer diagnosis
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marcus Vetter, PD Dr. med. | Contact | +41 61 925 27 15 | marcus.vetter@ksbl.ch | |
| Nicola Aceto, Prof. Dr. med. | Contact | +41 44 633 40 23 | nicola.aceto@biol.ethz.ch |
| Name | Affiliation | Role |
|---|---|---|
| Marcus Vetter, PD Dr. med. | Kantonsspital Baselland, Liestal | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Basel | Recruiting | Basel | 4031 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D009360 | Neoplastic Cells, Circulating |
| ID | Term |
|---|---|
| D009362 | Neoplasm Metastasis |
| D009385 | Neoplastic Processes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D001800 | Blood Specimen Collection |
| ID | Term |
|---|---|
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
Not provided
Not provided
Not provided
Not provided
Not provided
CTC cultures stored in the refrigerator. A "Biobank Reglement" is enclosed to this protocol.
| Department Oncology, Haematology & Immuntherapy, Kantonsspital Baselland | Recruiting | Liestal | 4410 | Switzerland |
|
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |